CLIN2 Awards: Funding Opportunity for Clinical Trials supports organizations conducting stem cell-based or genetic therapy trials to address serious unmet medical needs and advance toward marketing approval.
CIRM removed the October 23, 2026 mandatory-consultation deadline notice and announced an updated CLIN2 Program Announcement. Submission instructions now specify that only the PI or delegate can start an application, the PI cannot be changed afterward, and most CIRM applications require both PI submission and verified organizational-official approval.
Funder: California Institute for Regenerative Medicine
Due Dates: January 15, 2027 (Mandatory consultation) | January 21, 2027, 2 PM PT (Application)
Funding Amounts: Up to $8 million–$15 million, depending on trial stage and applicant status, for up to four years
Summary: Supports completion of phase 1, 2, or 3 clinical trials of stem cell-based or genetic therapies addressing serious unmet medical needs.
Key Information: Applicants must have at least one California trial site and meet FDA readiness and IND sponsorship requirements.
The California Institute for Regenerative Medicine’s CLIN2 program supports completion of a single interventional phase 1, 2, or 3 clinical trial, including pivotal trials, for an innovative stem cell-based or genetic therapy. Projects must address a serious unmet medical need and offer potentially transformative benefits for patients, families, and the healthcare system. Essential natural history or lead-in healthy volunteer studies may also be supported; healthy volunteer studies must share the interventional trial’s approved protocol.
Trials should form part of a broader development strategy aimed at marketing approval. CIRM emphasizes representative enrollment, stage-appropriate patient access and commercialization planning, and data sharing. Alongside funding, CIRM provides internal expertise and access to external experts to help advance clinical development.